ID: ALA156506

Max Phase: Preclinical

Molecular Formula: C16H10Cl2N2O2

Molecular Weight: 333.17

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(Cl)c1

Standard InChI:  InChI=1S/C16H10Cl2N2O2/c17-9-4-3-5-10(8-9)19-14-13(15(21)20-16(14)22)11-6-1-2-7-12(11)18/h1-8H,(H2,19,20,21,22)

Standard InChI Key:  OBJPHIOAHHIJPG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 333.17

Molecular Weight (Monoisotopic): 332.0119

AlogP: 3.47

#Rotatable Bonds: 3

Polar Surface Area: 58.20

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.77

CX Basic pKa:

CX LogP: 3.16

CX LogD: 3.15

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.85

Np Likeness Score: -0.75

References

1. Smith DG, Buffet M, Fenwick AE, Haigh D, Ife RJ, Saunders M, Slingsby BP, Stacey R, Ward RW..  (2001)  3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).,  11  (5): [PMID:11266159] [10.1016/s0960-894x(00)00721-6]

2. Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, Atallah N..  (2008)  Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.,  51  (7): [PMID:18324764] [10.1021/jm7009765]

3. Simon Townson and Suzanne Gokool. GlaxoSmithKline Published Kinase Inhibitor Set 2 Onchocerca lienalis Screening Data,  [10.6019/CHEMBL3988181]

4. Serafim RAM, Sorrell FJ, Berger BT, Collins RJ, Vasconcelos SNS, Massirer KB, Knapp S, Bennett J, Fedorov O, Patel H, Zuercher WJ, Elkins JM..  (2021)  Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.,  64  (18.0): [PMID:34463505] [10.1021/acs.jmedchem.0c01579]

5. Wells CI, Kapadia NR, Couñago RM, Drewry DH..  (2018)  In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases.,  9  (1): [PMID:30108900] [10.1039/C7MD00510E]

Source

Source(2):

• Scientific Literature
• Published Kinase Inhibitor Set 2